Oddo BHF Asset Management Sas Makes New $2.59 Million Investment in Avantor, Inc. (NYSE:AVTR)

Oddo BHF Asset Management Sas bought a new position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 99,970 shares of the company's stock, valued at approximately $2,586,000.

Several other institutional investors and hedge funds have also made changes to their positions in AVTR. Blue Trust Inc. lifted its holdings in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company's stock worth $31,000 after buying an additional 1,391 shares during the last quarter. UMB Bank n.a. bought a new position in shares of Avantor in the 3rd quarter worth about $49,000. Nisa Investment Advisors LLC boosted its holdings in shares of Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after buying an additional 835 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock worth $70,000 after purchasing an additional 1,285 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in Avantor by 278.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company's stock valued at $130,000 after purchasing an additional 3,700 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AVTR. Wells Fargo & Company dropped their target price on Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Monday, October 28th. Robert W. Baird cut their price objective on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Royal Bank of Canada restated an "outperform" rating and issued a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th. Barclays dropped their price target on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. Finally, UBS Group decreased their price objective on Avantor from $30.00 to $29.00 and set a "buy" rating for the company in a report on Tuesday, October 8th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Avantor has an average rating of "Moderate Buy" and an average price target of $27.69.

Avantor Price Performance

Shares of NYSE:AVTR traded down $0.20 during trading hours on Friday, hitting $22.33. 3,578,948 shares of the company's stock traded hands, compared to its average volume of 6,472,614. The company's fifty day simple moving average is $22.47 and its two-hundred day simple moving average is $23.53. The company has a market cap of $15.20 billion, a price-to-earnings ratio of 48.54, a price-to-earnings-growth ratio of 2.75 and a beta of 1.29. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor, Inc. has a 52 week low of $19.59 and a 52 week high of $28.00.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.